May 19, 2024, 05:07
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC – Top Science
Top Science shared on X:
“This is the first prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced Non- Small Cell Lung Cancer (NSCLC).
Sintilimab was efficacious and well-tolerated irrespective of PD-L1 expression level in patients with advanced NSCLC and had similar efficacy and safety to Pembrolizumab.”
Additional information.
Source: Top Science/X
anti-PD-1 antibodies
Bin Gan
Bin-Chao Wang
cancer
Chong-Rui Xu
E-E Ke
Hai-Yan Tu
Hong-Hong Yan
Hua-Jun Chen
Jia-Xin Lin
Jia-Yi Deng
Jie Huang
Jin-Ji Yang
Ming-Yi Yang
Ming-Ying Zheng
NSCLC
OncoDaily
Oncology
pembrolizumab
Qing Zhou
Si-Yang Maggie Liu
Sintilimab
Top Science
Wen-Zhao Zhong
Xu-Chao Zhang
Yang-Si Li
Yangqiu Li
Yi-Long Wu
Zhen Wang